Activation of PPARγ by Rosiglitazone Does Not Negatively Impact Male Sex Steroid Hormones in Diabetic Rats

Abstract EN

Peroxisome proliferator-activated receptor gamma (PPARγ) activation decreased serum testosterone (T) in women with hyperthecosis and/or polycystic ovary syndrome and reduced the conversion of androgens to estradiol (E2) in female rats.

This implies modulation of female sex steroid hormones by PPARγ.

It is not clear if PPARγ modulates sex steroid hormones in diabetic males.

Because PPARγ activation by thiazolidinedione increased insulin sensitivity in type 2 diabetes, understanding the long term impact of PPARγ activation on steroid sex hormones in males is critical.

Our objective was to determine the effect of PPARγ activation on serum and intratesticular T, luteinizing hormone (LH), follicle stimulating hormone (FSH) and E2 concentrations in male Zucker diabetic fatty (ZDF) rats treated with the PPARγ agonist rosiglitazone (a thiazolidinedione).

Treatment for eight weeks increased PPARγ mRNA and protein in the testis and elevated serum adiponectin, an adipokine marker for PPARγ activation.

PPARγ activation did not alter serum or intratesticular T concentrations.

In contrast, serum T level but not intratesticular T was reduced by diabetes.

Neither diabetes nor PPARγ activation altered serum E2 or gonadotropins FSH and LH concentrations.

The results suggest that activation of PPARγ by rosiglitazone has no negative impact on sex hormones in male ZDF rats.